Cyclacel Pharmaceuticals, Inc. Release: Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.

Help employers find you! Check out all the jobs and post your resume.

Back to news